PT3638370T - Tratamento para hemicrania - Google Patents

Tratamento para hemicrania

Info

Publication number
PT3638370T
PT3638370T PT187491246T PT18749124T PT3638370T PT 3638370 T PT3638370 T PT 3638370T PT 187491246 T PT187491246 T PT 187491246T PT 18749124 T PT18749124 T PT 18749124T PT 3638370 T PT3638370 T PT 3638370T
Authority
PT
Portugal
Prior art keywords
migraine
treatment
Prior art date
Application number
PT187491246T
Other languages
English (en)
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of PT3638370T publication Critical patent/PT3638370T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT187491246T 2017-06-14 2018-06-25 Tratamento para hemicrania PT3638370T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine

Publications (1)

Publication Number Publication Date
PT3638370T true PT3638370T (pt) 2021-01-26

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187491246T PT3638370T (pt) 2017-06-14 2018-06-25 Tratamento para hemicrania

Country Status (25)

Country Link
US (1) US11471434B2 (pt)
EP (1) EP3638370B1 (pt)
JP (1) JP7130739B2 (pt)
KR (1) KR102594130B1 (pt)
CN (1) CN111093772B (pt)
AU (1) AU2018284330B2 (pt)
BR (1) BR112019026660A2 (pt)
CA (1) CA3067321A1 (pt)
CY (1) CY1123860T1 (pt)
DK (1) DK3638370T3 (pt)
ES (1) ES2847169T3 (pt)
GB (1) GB201709459D0 (pt)
HR (1) HRP20210108T1 (pt)
HU (1) HUE053089T2 (pt)
IL (1) IL271211B2 (pt)
LT (1) LT3638370T (pt)
MA (1) MA49396B1 (pt)
MD (1) MD3638370T2 (pt)
MX (1) MX2019014784A (pt)
PL (1) PL3638370T3 (pt)
PT (1) PT3638370T (pt)
RS (1) RS61481B1 (pt)
SG (1) SG11201912146RA (pt)
SI (1) SI3638370T1 (pt)
WO (1) WO2018229738A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019159110A1 (en) 2018-02-15 2019-08-22 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
BR112021010923A2 (pt) * 2018-12-06 2021-08-24 Intrabio Ltd Análogos deuterados de acetileucina

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
DE602004019530D1 (de) * 2003-07-03 2009-04-02 Euro Celtique Sa 2-pyridin alkyne derivaten und ihre verwendung für die schmerzbehandlung
DK1648879T3 (da) * 2003-07-24 2009-02-23 Euro Celtique Sa Heteroaryl-tetrahydropyridyl-forbindelser, der er anvendelige til behandling eller forebyggelse af smerte
CN1856489A (zh) * 2003-09-22 2006-11-01 欧洲凯尔特公司 用于治疗疼痛的苯甲酰胺化合物
WO2005030753A2 (en) * 2003-09-22 2005-04-07 Euro-Celtique S.A. Therapeutic agents useful for treating pain
SI1727801T1 (sl) * 2003-12-30 2009-06-30 Euro Celtique Sa Piperazini, koristni za zdravljenje bolečine
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
JP5876423B2 (ja) * 2010-06-22 2016-03-02 塩野義製薬株式会社 Trpv1阻害活性を有する化合物とその使用
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
JP6092113B2 (ja) * 2010-11-09 2017-03-08 マンカインド コーポレイション セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物
WO2013021276A1 (en) * 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
SG10202106190RA (en) 2016-04-19 2021-07-29 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
SI3359146T1 (sl) 2016-08-11 2019-05-31 Intrabio Ltd Farmacevtski sestavki in uporabe, usmerjene na motnje lisosomalnega skladiščenja
HUE045043T2 (hu) 2016-08-11 2019-12-30 Intrabio Ltd Terápiás szerek neurodegeneratív betegségekre
EP4234022A3 (en) 2017-03-28 2023-10-04 IntraBio Ltd Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
EP3697406A1 (en) 2017-10-18 2020-08-26 IntraBio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
CA3079194A1 (en) 2017-10-18 2019-04-25 Intrabio Limited Therapeutic agents for neurodegenerative diseases
WO2019159110A1 (en) 2018-02-15 2019-08-22 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
BR112021010923A2 (pt) 2018-12-06 2021-08-24 Intrabio Ltd Análogos deuterados de acetileucina
SG11202109512SA (en) 2019-03-02 2021-09-29 Intrabio Ltd Leucine, acetyl leucine, and related analogs for treating disease
WO2020261230A1 (en) 2019-06-28 2020-12-30 Intrabio Ltd. Combination therapy with acetyl-leucine and miglustat
US20230051742A1 (en) 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Also Published As

Publication number Publication date
RU2020100475A3 (pt) 2021-10-22
PL3638370T3 (pl) 2021-05-17
MX2019014784A (es) 2021-11-16
AU2018284330A1 (en) 2020-01-02
KR102594130B1 (ko) 2023-10-24
EP3638370A1 (en) 2020-04-22
CY1123860T1 (el) 2022-05-27
US11471434B2 (en) 2022-10-18
KR20210013518A (ko) 2021-02-04
HUE053089T2 (hu) 2021-06-28
GB201709459D0 (en) 2017-07-26
CA3067321A1 (en) 2018-12-20
RU2020100475A (ru) 2021-07-14
IL271211A (en) 2020-01-30
BR112019026660A2 (pt) 2020-07-14
JP2020526575A (ja) 2020-08-31
IL271211B1 (en) 2023-09-01
WO2018229738A1 (en) 2018-12-20
EP3638370B1 (en) 2020-11-11
HRP20210108T1 (hr) 2021-03-19
ES2847169T3 (es) 2021-08-02
US20200253905A1 (en) 2020-08-13
JP7130739B2 (ja) 2022-09-05
MD3638370T2 (ro) 2021-04-30
SG11201912146RA (en) 2020-01-30
MA49396B1 (fr) 2021-03-31
MA49396A (fr) 2020-04-22
RS61481B1 (sr) 2021-03-31
DK3638370T3 (da) 2021-01-25
SI3638370T1 (sl) 2021-04-30
IL271211B2 (en) 2024-01-01
LT3638370T (lt) 2021-03-25
CN111093772B (zh) 2023-11-03
AU2018284330B2 (en) 2024-03-14
CN111093772A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
IL265343A (en) Treatment of persistent migraine
IL291153A (en) Methods for treating or preventing migraine headaches
IL269371A (en) Treatment methods
GB201608885D0 (en) Treatment
GB2567616B (en) Treatment method
GB201811679D0 (en) Treatment apparatus
GB2571601B (en) Treatment method
EP3507838C0 (fr) Dispositif de traitement de pièces
SG11202001806TA (en) Treatment method
IL271211A (en) Migraine treatment
IL270867A (en) Treatment method
SG10201913377VA (en) Treatment apparatus
PT3250218T (pt) Péptido natkide para o tratamento da obesidade
GB201718985D0 (en) Treatment
ZA201805215B (en) Preparation for nasal-nasopharyngeal treatment
GB201713650D0 (en) Treatment
GB201706955D0 (en) Treatment
GB201711677D0 (en) Combination treatment
GB201704949D0 (en) Combination treatment
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment
GB201617380D0 (en) Treatment for Osteoarthritis